25th January 2024
EIT Health is opening a call for expression of interest for participation in the ‘Start-ups Meet Pharma’ and “Startups Meet Healthcare Providers” programmes. The EIT Health Programmes ‘Start-ups Meet Pharma’ and “Startups Meet Healthcare Providers” are challenge-based acceleration programmes connecting key pharma partners and healthcare providers in Europe with startups at the forefront of technology innovation.
As the healthcare landscape rapidly evolves, it is more important than ever for pharma companies and healthcare providers to embrace new ideas and approaches. By partnering with start-ups, they can leverage the latest technologies and insights to develop new treatments and improve patient care.
Building on the success of previous editions, the programmes will continue its mission to foster collaboration, explore partnership opportunities, and introduce breakthrough solutions within the healthcare sector. The programmes take no equity or IP involvement and since their launch they have helped forge 28 partnerships across the industry. Past sponsors include industry titans like Pfizer, Bayer, Amgen, Boehringer Ingelheim, Sanitas, Diakonie Baden-Württemberg and many more.
We are thrilled to launch Startups Meets Pharma and startups Meet Healthcare Providers again in 2024, continuing our tradition of connecting visionary startups with key players in the healthcare industry. The programs have proven instrumental in driving innovation, making it a win-win for both startups and established industry leaders,” said Kurt Höller, Managing Director, EIT Health Germany – Switzerland.
EIT Health encourages interested pharmaceutical companies and healthcare organizations to submit their challenges. The submission deadline is 30 April 2024, providing an excellent opportunity to contribute to shaping the future of healthcare.
For more information, send an e-mail to: clc.germany@eithealth.eu
Corify Care raises €6M to revolutionise cardiac care
A significant milestone for the company.
Luminate Medical secures additional $2.5M to advance cancer care
A significant milestone for the company.
Longenesis teams up with Novartis for digital heart care innovation
Pilot project for treatment of cardiovascular diseases.